CTIS2023-508630-34-00招募中1 期
J1I-MC-GZBO: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index =27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. - J1I-MC-GZBO
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Must be 45 years old or older, Have BMI of >27.0 kg/m2, Have established ASCVD and/or CKD, With or without T2D as long as HbA1c<10%
排除标准
- •Have Type 1 Diabetes, Have had or plan to have a surgical treatment for obesity, Have an eGFR <20 mL/min/1.73 m2 at screening, Have any of the following cardiovascular conditions = 90 days prior to randomization: Myocardial infarction, Acute coronary syndrome, Stroke, or coronary, peripheral, or carotid artery arterial revascularization procedure, Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2, Have acute decompensated heart failure requiring hospitalization, Have New York Heart Association (NYHA) Classification Class IV heart failure at screening
研究者
相似试验
招募中
1 期
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)Cardiovascular Disease, ObesityCTIS2023-503659-88-00Eli Lilly & Co.1,800
招募中
1 期
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)Type 2 DiabetesCTIS2023-507280-18-00Eli Lilly & Co.520
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)Obesity, Overweight, Overweight or ObesityCTIS2022-502839-19-00Eli Lilly & Co.3,000
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)Overweight, Obesity, Type 2 DiabetesCTIS2022-502837-24-00Eli Lilly & Co.1,460
招募中
1 期
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCTIS2023-504583-42-00Eli Lilly & Co.120